$IONSIONIS PHARMACEUTICALS INC

📅 Upcoming

🕒 Recent(90d)

News

• BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
  BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.
  biospace · 3h ago
• Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
  Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.
  biospace · 2d ago
• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
  biopharma_dive · 5d ago
• Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
  In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis.
  biospace · 5d ago
• 5 companies advancing ATTR assets in the wake of Wainua’s fail
  The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five con…
  biospace · 9d ago
• Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
  After 37 years, Frank Bennett is retiring from Ionis Pharmaceuticals. Bennett started at Ionis as a founding scientist in 1989 and climbed to the role of CSO. Bennett will retire in February 2027,…
  endpoints · 12d ago
• Alnylam plunges as earnings deliver ‘one-two punch’
  The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
  biopharma_dive · 12d ago
• Chutes & Ladders—Legend CEO departs without successor in place
  Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
  fiercebiotech · 12d ago
• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
  With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
  biospace · 13d ago
• FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
  Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.
  biopharma_dive · 14d ago